Therapeutic indications of intravenous immunoglobulins;Les indications thérapeutiques des immunoglobulines intraveineuses

Transfusion Clinique et Biologique

Volumn 10, Issue 3, 2003, Pages 179-184

  Tellier, Z ^a   Mouthon, L ^b  

^a Dir Affaires Medicales/Rech Clin   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Auto immune disease; Immune humoral deficiencies; Intravenous Immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DERMATOMYOSITIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NEUROPATHY; POLYMYOSITIS; POLYRADICULONEUROPATHY; RETINOPATHY; THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; VASCULITIS;

EID: 0037701336     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(03)00043-0     Document Type: Conference Paper

References (40)

1. Courtay A, Couturon I, Charpentier E, Viens-Bitker C, Guillevin L, Étienne JP, Fery-Lemonnier E. Évolution des prescriptions des Immunoglobulines intraveineuses polyvalentes (IgIV) à l'Assistance Publique Hôpitaux de Paris entre 1988 et 1997. Ann Med Interne 2000;151(suppl. 1):1S5-1S12.
2. Coutinho A, Kazatchkine MD, Avrameas S. Natural auto-antibodies. Curr Opin Immunol 1995;7:812-8.
3. Kazatchkine MD, Kaveri SV. Immunomodulation of auto-immune and inflammatory diseases with intravenous immune globulins. N Engl J Med 2001;345:747-55.
4. Note for Guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). The European Agency for the Evaluation of Medicinal Products CPMP/BPWG/388/95 rev. 1.
5. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia. A review. Am J med 1984;76:53-60.
6. Liese JG, Wintergest U, Tympner KD, Belohradsky BH. High vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992;146:335-9.
7. Griffiths H, Brennen V, Lea J, Bunch C, Lee M, Chapel H. Cross over study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989;73:366-8.
8. Chapel HM, Lee M, Hargreaves R, Phamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343:1059-63.
9. Mofenson LM, Moye Jr J, Bethel J, Hirschhorn R, Jordan C, Nugent R. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 × 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Jama 1992;268:483-8.
10. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, et al. A controlled trial of long term administration of intravenous immunoglobulin to prevent late infection and chronic graft-versus host disease following bone marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1995;2:44-53.
11. Sullivan KM, Kopecky KG, Jocom J, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323:705-9.
12. Winston DJ, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001 Jul;28(2):187-96.
13. Mouthon L, Lortholary O. Intravenous Immunoglobulin (IVIg) therapy in infectious diseases: where do we stand? (editorial). Clin Microbiol Infect 2003 (Sous presse).
14. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in chilhood. Lancet 1981;1:1228-317.
15. Godeau B,Chevret S, Varet B, Lefrere F, Zini JM, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe auto-immune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359(9300):23-9.
16. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7.
17. Van der Meché FGA, Schmitz PIM, Dutch Guillain- Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-9.
18. Hughes RA. Intravenous IgG in Guillain-Barré syndrome. Br Med J 1996;313:376-7.
19. Vermeulen M, Van Doorn PA, Brand A, Strenghers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56(1):36-9.
20. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled, cross-over study. Brain 1996;119:1067-77.
21. Thompson N, Choudhary, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996;243(3):280-5.
22. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagarajah HN, et al. Randomized controlled trial of IVIG in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56(4):445-9.
23. Dick PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36(6):838-45.
24. Hughes R, Bensa, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immune globulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50(2):195-201.
25. Van Schaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database Syst Rev 2002(2):CD001797.
26. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high dose of immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-96.
27. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
28. Chérin P, Herson S, Wechsler B, Piette JC, Blétry O, Ziza JM, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990;336:ii;116.
29. Chérin P, Herson S, Wechsler B, Piette JC, Blétry O, Coutellier A, et al. Efficacy of intravenous gamma globulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991;91:162-8.
30. Chérin P, Piette JC, Wechsler B, Blétry O, Ziza JM, Laraki R, et al. Intravenous gammaglobulin as first line therapy in polymyositis and dermatomyositis: a report of 11 cases. J Rheumatol 1994;21:1092-7.
31. Chérin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with 35 adult patients. Arthritis Rheumatol 2002 Feb;46(2):467-74.
32. Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study. Brain 2001;124:145-153.
33. Comi G, Nemni R, Amadio S, Galrdi G, Leocani L. Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune mediated neuropathies. Mult Scler 1997;3:93-7.
34. Le Hoang P, Cassoux N, Georges F, Kullman N, Kazatchkine MD. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000;8:49-57.
35. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in Multiple sclerosis: effect on relapses. Neurology 1998;50:398-402.
36. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-93.
37. Sorensen PS, Wansher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-81.
38. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345(26):1870-6 27.
39. Jayne DR, Lockwood CM. Pooled intravenous immune globulin in the management of systemic vasculitis. Adv Exp Med Biol 1993;336:469-72.
40. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood CM. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000 Jul;93:433-9.